Skip to main content
SpringerLink
Log in

Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study

  • Clinical Study - Patient Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

We tested the efficacy and safety of temozolomide (TMZ) when given concomitantly to radiotherapy only in the first and last weeks of treatment to patients affected by high grade gliomas. Conformal radiotherapy (CTV1: tumor bed + residual tumor if present + 1.5 cm, 5,940 cGy, 180 cGy/day; CTV2: oedema, 3,960 cGy, 180 cGy/day) was associated with TMZ, 75 mg/m2 × 5 days, the first and last weeks of radiotherapy. Adjuvant chemotherapy with TMZ (150 mg/mq daily × 5 days, q28 on the first cycle, 200 mg/mq daily × 5 days, q28 for the following cycles) was given, after chemoradiation, until disease progression or up to 6 cycles. From October 2000 to December 2003, 29 patients (25 GBL, 86.2%; 4 AA, 13.8%) were enrolled in this study. Twenty-two patients (75.8%) received a median 6 cycles of adjuvant chemotherapy with TMZ (range 1–20). Hematological toxicity was absent during concomitant chemoradiation and mild in adjuvant therapy, while neurological toxicity (seizures) was observed only in one case. At a median follow-up of 66 months (range 3–96), median progression-free survival (PFS) was 8 months, with a 1- and 2-year PFS of 46.7 and 28.7%, respectively; median overall survival (OS) time was 21 months, with a 1- and 2-year OS of 69.2 and 42.3%, respectively. In our experience, TMZ proved to be effective even when given only during the first and the last week of radiotherapy, with lower hematological toxicity.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. When PY, Kesari S (2008) Malignant gliomas in adults. N Engl J Med 359:492–507

    Article  Google Scholar 

  2. Asthagiri AR, Pouratian N, Sherman J, Ahmed G, Shaffrey ME (2007) Advances in brain tumor surgery. Neurol Clin 25:975–1003

    Article  PubMed  Google Scholar 

  3. Lacroix M, Abi Said D, Foumey DR et al (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95:190–198

    Article  CAS  PubMed  Google Scholar 

  4. Laperriere N, Zuraw L, Cairncross G (2002) Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother Oncol 64:259–273

    Article  PubMed  Google Scholar 

  5. Levin V, Leibel S, Gutin P (1997) Neoplasms of the central nervous system. In: DeVita V Jr, Hellman S, Rosenberg S (eds) Cancer: principles and practice of oncology. Lippincott-Raven, Philadelphia, pp 2022–2082

    Google Scholar 

  6. DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123

    Article  CAS  PubMed  Google Scholar 

  7. Galanis E, Buckner J (2000) Chemotherapy for high-grade gliomas. Br J Cancer 82:1371–1380

    CAS  PubMed  Google Scholar 

  8. Fine HA, Dear KBG, Loeffler JS, Black PM, Canellos GP (1993) Meta-analysis of radiation therapy with and without adjuvant chemo-therapy for malignant gliomas in adults. Cancer 71:2585–2597

    Article  CAS  PubMed  Google Scholar 

  9. Stewart LA (2002) Chemotherapy in adult high-grade glioma: a systematic review and meta-analysis of individual patient data from 12 randomised trials. Lancet 359:1011–1018

    Article  CAS  PubMed  Google Scholar 

  10. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996

    Article  CAS  PubMed  Google Scholar 

  11. Hirose Y, Berger MS, Pieper RO (2001) p53 effects both the duration of G2/M arrest and the fate of temozolomide-treated human glioblastoma cells. Cancer Res 61:1957–1963

    CAS  PubMed  Google Scholar 

  12. Wedge SR, Porteous JK, Glaser MG, Marcus K, Newlands ES (1997) In vitro evaluation of temozolomide combined with X-irradiation. Anticancer Drugs 8:92–97

    Article  CAS  PubMed  Google Scholar 

  13. Friedman HS, Mc Lendon RE, Kerby T et al (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857

    CAS  PubMed  Google Scholar 

  14. Brandes AA, Tosoni A, Cavallo G et al (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155–1160

    Article  CAS  PubMed  Google Scholar 

  15. Wong S, Rosenthal MA, Dowling A et al (2006) Phase II study of two-weekly temozolomide in patients with high-grade gliomas. J Clin Neurosci 13:18–22

    Article  CAS  PubMed  Google Scholar 

  16. Yates JW, Chalmer B, McKegney FP (1980) Evaluation of patients with advanced cancer using the Karnofsky Performance Status. Cancer 45:2220–2224

    Article  CAS  PubMed  Google Scholar 

  17. Curran WJ, Scott CB, Horton J et al (1993) Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J Natl Cancer Inst 85:704–710

    Article  PubMed  Google Scholar 

  18. Radiation Therapy Oncology Group (1999) Cooperative group common toxicity criteria v 2.0. www.rtog.org/members/toxicity/tox.html

  19. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205–216

    Article  CAS  PubMed  Google Scholar 

  20. Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481

    Article  Google Scholar 

  21. Cox DR (1972) Regression model and life tables. J R Stat Soc 34:187–220

    Google Scholar 

  22. Green SB, Byar DP, Walker MD et al (1983) Comparisons of carmustine, procarbazine, and high-dose methylprednisolone as additions to surgery and radiotherapy for treatment of malignant glioma. Cancer Treat Rep 67:121–132

    CAS  PubMed  Google Scholar 

  23. Shapiro WR, Green SB, Burger PC et al (1989) Randomized trial of three chemotherapy regimens and two radiotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma: Brain Tumor Cooperative Group trial 8001. J Neurosurg 71:1–9

    Article  CAS  PubMed  Google Scholar 

  24. Stupp R, Hegi ME (2003) Recent developments in the management of malignant glioma. In: Perry MC (ed) ASCO 2003 educational book. American Society of Clinical Oncology, Alexandria, pp 779–788

    Google Scholar 

  25. Shapiro WR (1992) Chemotherapy of malignant gliomas: studies of the BTCG. Rev Neurol 148:428–434

    CAS  PubMed  Google Scholar 

  26. Grossman SA, O’Neill A, Grunnet M et al (2003) Phase III study comparing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multiforme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol 21:1485–1491

    Article  CAS  PubMed  Google Scholar 

  27. Deutsch M, Green SB, Strike TA et al (1989) Results of a randomized trial comparing BCNU plus radiotherapy, streptozotocin plus radiotherapy, BCNU plus hyperfractionated radiotherapy, and BCNU following misonidazole plus radiotherapy in the postoperative treatment of malignant glioma. Int J Radiat Oncol Biol Phys 16:1389–1396

    CAS  PubMed  Google Scholar 

  28. Lanzetta G, Campanella C, Rozzi A et al (2003) Temozolomide in radio-chemotherapy combined treatment for newly diagnosed glioblastoma multiforme: phase II clinical trial. Anticancer Res 23:5159–5164

    CAS  PubMed  Google Scholar 

  29. Chibbaro S, Benvenuti L, Caprio A et al (2004) Temozolomide as first-line agent in treating high-grade gliomas: phase II study. J Neurooncol 67:77–81

    Article  CAS  PubMed  Google Scholar 

  30. Kocher M, Kunze S, Eich HT, Semrau R, Müller RP (2005) Efficacy and toxicity of postoperative temozolomide radiochemotherapy in malignant glioma. Strahlenther Onkol 181:157–163

    Article  PubMed  Google Scholar 

  31. Valentini V, Coco C, Cellini N et al (1999) Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys 45:1175–1184

    Article  CAS  PubMed  Google Scholar 

  32. Mancuso S, Smaniotto D, Benedetti-Panici PL et al (2000) Phase I-II trial of preoperative chemoradiation in locally advanced cervical carcinoma. Gynecol Oncol 78:324–328

    Article  CAS  PubMed  Google Scholar 

  33. Nigro ND, Seydel HG, Considine B et al (1983) Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal. Cancer 51:1826–1829

    Article  CAS  PubMed  Google Scholar 

  34. D’Agostino G, Balducci M, Anile C et al (2007) An analysis of two different schedules of radiochemotherapy with concomitant temozolomide in high grade gliomas. Proc Am Soc Clin Oncol 25:A2035

    Google Scholar 

  35. Combs SE, Wagner J, Bischof M et al (2008) Postoperative treatment of primary glioblastoma multiforme with radiation and concomitant temozolomide in elderly patients. Int J Radiat Oncol Biol Phys 70:987–992

    PubMed  Google Scholar 

  36. Combs SE, Wagner J, Bischof M et al (2008) Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys 71:999–1005

    CAS  PubMed  Google Scholar 

  37. Kocher M, Frommolt P, Borberg SK et al (2008) Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol 184:572–579

    Article  PubMed  Google Scholar 

  38. Sridhar T, Gore A, Boiangiu I et al (2009) Concomitant (without adjuvant) temozolomide and radiation to treat glioblastoma: a retrospective study. Clin Oncol (R Coll Radiol) 21:19–22

    CAS  Google Scholar 

  39. Mrugala MM, Chamberlain MC (2008) Mechanisms of disease: temozolomide and glioblastoma—look to the future. Nat Clin Pract Oncol 5:476–486

    Article  CAS  PubMed  Google Scholar 

  40. Wasserfallen JB, Ostermann S, Pica A et al (2004) Can we afford to add chemotherapy to radiotherapy for glioblastoma multiforme? Cost-identification analysis of concomitant and adjuvant treatment with temozolomide until patient death. Cancer 101:2098–2105

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiotherapy, Catholic University of the Sacred Heart, Largo A. Gemelli, 8, 00168, Rome, Italy

    Mario Balducci, Giuseppe Roberto D’Agostino, Stefania Manfrida, Filippo De Renzi, Giuseppina Apicella, Alba Fiorentino, Vincenzo Frascino, Giovanna Mantini, Berardino De Bari, Vincenzo Valentini & Numa Cellini

  2. Department of Neurosurgery, Catholic University of the Sacred Heart, Rome, Italy

    Gabriella Colicchio, Annunziato Mangiola, Angelo Pompucci & Carmelo Anile

Authors
  1. Mario Balducci
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Giuseppe Roberto D’Agostino
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stefania Manfrida
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Filippo De Renzi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Gabriella Colicchio
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Giuseppina Apicella
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Annunziato Mangiola
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Alba Fiorentino
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Vincenzo Frascino
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Giovanna Mantini
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Berardino De Bari
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Angelo Pompucci
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Vincenzo Valentini
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Carmelo Anile
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Numa Cellini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Roberto D’Agostino.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Balducci, M., D’Agostino, G.R., Manfrida, S. et al. Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study. J Neurooncol 97, 95–100 (2010). https://doi.org/10.1007/s11060-009-9997-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11060-009-9997-y

Keywords

Search

Navigation